Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656916 | 1.00 | ATM (0.52) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL3656918 | 1.00 | ATM (0.52) | ATMCTSKELANECTRB1CTSS | |
| Methylsulfanylmethane SCHEMBL6213966 | 0.94 | ATM (0.47) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL16473698 | 0.86 | ATM (0.54) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL14317559 | 0.86 | ATM (0.54) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL14247228 | 0.86 | ATM (0.54) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL24323665 | 0.84 | ALDH1A1 (0.58) | CTSKCTSSCTSLALDH1A1ALOX15 | |
| SCHEMBL24323651 | 0.84 | ALDH1A1 (0.58) | CTSKCTSSCTSLALDH1A1ALOX15 | |
| SCHEMBL1632289 | 0.84 | ATM (0.50) | ATMCTSKELANECTRB1CTSS | |
| SCHEMBL19548687 | 0.84 | TGM2 (0.53) | CTSKCTSLALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005013909-A2 | NOVEL CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040229863-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-11-18 | — | — | US | disclosed |
| EP-1392657-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2003053331-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030114437-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | disclosed |
| WO-2003045909-A2 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF AZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-1278502-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-1278502-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114437-A1 | Protease inhibitors | CTSS, CTSE, CTSF | ATM 3119/4885CTSK 6/4885ELANE 14/4885 |
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | ATM 3624/4885CTSK 1/4885ELANE 201/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | ATM 3585/4885CTSK 1/4885ELANE 152/4885 |
| US-20040229863-A1 | Protease inhibitors | CTSS, CTSE, CTSF | ATM 3119/4885CTSK 6/4885ELANE 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.